Overview
Mermaid diagram (expand to render)
The University of Miami Miller School of Medicine, located in Miami, Florida, represents one of the leading institutions for neurodegenerative disease research and clinical care in the southeastern United States. As a major academic medical center with a diverse patient population, the institution has made significant contributions to understanding and treating Alzheimer's disease, Parkinson's disease, ALS, and related disorders["@miami2024"].
The university's strategic location provides unique opportunities to study neurodegenerative diseases in diverse populations, including substantial Hispanic and Caribbean communities that are underrepresented in most research studies. The Miller School of Medicine's Parkinson's Foundation Center of Excellence and Memory Disorders Program provide comprehensive clinical care while advancing research into disease mechanisms and novel therapeutics.
Research Programs
Parkinson's Disease Research
Miami's Parkinson's disease program benefits from the Parkinson's Foundation Center of Excellence designation, which recognizes the comprehensive, multidisciplinary approach to patient care and the strong research program. The program encompasses basic science research, clinical investigations, and surgical interventions[@kalia2015].
Major research areas include:
- Deep Brain Stimulation: Advanced deep brain stimulation programming and surgical services for movement disorders. The program has extensive experience with DBS targeting the subthalamic nucleus and globus pallidus internus for patients with advanced Parkinson's disease. Research focuses on optimizing stimulation parameters, reducing side effects, and improving outcomes[@okun2019].
- Non-Motor Symptoms: Comprehensive characterization and treatment of sleep disorders, autonomic dysfunction, and cognitive impairment in Parkinson's disease. Studies have demonstrated that non-motor symptoms often precede motor symptoms and can serve as early markers of neurodegeneration[@tolosa2021].
- Neuroprotection: Clinical trials testing disease-modifying therapies targeting alpha-synuclein pathology. The program participates in multi-center trials of alpha-synuclein antibodies, LRRK2 inhibitors, and other experimental treatments.
- Genetics: Investigation of genetic risk factors in diverse populations, including studies on GBA, LRRK2, and other genes in Hispanic and Caribbean populations.
ALS and Motor Neuron Disease Program
The ALS program at Miami is one of the largest in the southeastern United States, providing comprehensive care for patients with ALS and related disorders while conducting cutting-edge research. The program brings together neurologists, pulmonologists, nutritionists, physical therapists, and social workers to provide multidisciplinary care[@schwid2020].
Research priorities include:
- Multidisciplinary Care: Integrated ALS clinic providing neurology, pulmonology, nutrition, and rehabilitation services. The clinic follows over 300 patients with ALS and related disorders.
- Clinical Trials: Participation in Phase 1-3 trials of novel ALS therapeutics, including antisense oligonucleotides targeting SOD1 and C9orf72, and small molecules for neuroprotection.
- Biomarker Studies: Collection and analysis of cerebrospinal fluid and blood biomarkers to monitor disease progression and treatment response. The program has established a biorepository with samples from over 500 patients.
- Genetics: Investigation of genetic factors in ALS, including studies on C9orf72 expansions and other known ALS genes in diverse populations[@andersen2016].
Alzheimer's Disease Research
The Memory Disorders Program at the University of Miami investigates all aspects of Alzheimer's disease and related dementias, with particular expertise in early detection, vascular contributions to dementia, and disease in diverse populations.
Research focus areas include:
- Early Detection: Identification of preclinical Alzheimer's in diverse populations through comprehensive cognitive testing and biomarker screening. Studies examine how cognitive test performance varies across different cultural and linguistic backgrounds.
- Vascular Contributions: Research on how hypertension, diabetes, and other vascular conditions interact with Alzheimer's pathology. This is particularly relevant given the high prevalence of cardiovascular risk factors in the Miami population[@marshall2019].
- Treatment Trials: Active enrollment in anti-amyloid and anti-tau clinical trials. The program has enrolled over 200 patients in clinical trials since 2015.
- Biomarkers: Development and validation of biomarkers for early detection, including cerebrospinal fluid and blood-based assays for amyloid and tau.
Key Research Focus Areas
Alpha-Synuclein Biology
University of Miami researchers have made significant contributions to understanding alpha-synuclein, the protein that accumulates in the brains of patients with Parkinson's disease and dementia with Lewy bodies. Research focuses on:
- How alpha-synuclein misfolds and aggregates into toxic species
- The prion-like propagation of alpha-synuclein pathology between brain regions
- Strain diversity among alpha-synuclein aggregates and their relationship to clinical phenotypes
- Strategies to prevent alpha-synuclein aggregation or enhance its clearance
Studies have demonstrated that alpha-synuclein can spread from cell to cell via exosomes, contributing to the progressive nature of Parkinson's disease[@volpicelli2021]. Research also examines how alpha-synuclein interacts with other proteins and cellular pathways to cause neuronal dysfunction.
Non-Motor Symptoms
Non-motor symptoms are a major research focus at the University of Miami, as these symptoms often have the greatest impact on patient quality of life. Research includes:
- Sleep Disorders: Studies on REM sleep behavior disorder as a prodromal marker of Parkinson's disease, and the prevalence and treatment of sleep disturbances in established Parkinson's disease[@postuma2015].
- Autonomic Dysfunction: Investigation of orthostatic hypotension, urinary dysfunction, and other autonomic symptoms in Parkinson's disease and related disorders.
- Cognitive Impairment: Research on mild cognitive impairment and dementia in Parkinson's disease, including studies on risk factors and potential treatments.
- Neuropsychiatric Symptoms: Studies on depression, anxiety, apathy, and psychosis in neurodegenerative diseases.
Vascular Contributions to Neurodegeneration
Miami's location and patient population have led to strong research programs on vascular contributions to neurodegeneration. Studies examine:
- How hypertension, diabetes, and other vascular risk factors influence Alzheimer's disease pathology and clinical expression
- The role of small vessel disease in cognitive decline
- Interactions between vascular and neurodegenerative pathologies
- Strategies to modify vascular risk factors to reduce dementia risk
This research is particularly important for the diverse Miami population, which has high rates of hypertension, diabetes, and other cardiovascular risk factors[@marshall2019].
Diversity in Neurodegeneration
The University of Miami is uniquely positioned to study neurodegenerative diseases in diverse populations. Research programs focus on:
- Understanding how genetic risk factors vary across different ethnic groups
- Adapting cognitive assessment tools for use in Spanish-speaking populations
- Investigating environmental and lifestyle factors that may influence disease risk in diverse communities
- Ensuring that clinical trial results are applicable to diverse populations
This research addresses a critical gap in the field, as most neurodegenerative disease research has been conducted in populations of European ancestry.
Clinical Programs
Parkinson's Foundation Center of Excellence
The University of Miami has been designated as a Parkinson's Foundation Center of Excellence, recognizing its comprehensive approach to Parkinson's disease care. The center provides:
- Movement disorder specialists with expertise in diagnosis and management
- Deep brain stimulation evaluation and programming
- Physical, occupational, and speech therapy
- Social work and support services
- Access to clinical trials
- Education and support groups for patients and families
The center follows over 2,000 patients with Parkinson's disease and related disorders, making it one of the largest Parkinson's programs in the country.
Memory Disorders Program
The Memory Disorders Program offers comprehensive evaluation and treatment for patients with:
- Alzheimer's disease
- Dementia with Lewy bodies
- Frontotemporal dementia
- Vascular dementia
- Mild cognitive impairment
Services include:
- Neuropsychological testing
- Neuroimaging
- Biomarker analysis
- Access to cutting-edge treatments and clinical trials
- Caregiver support and education
ALS Multidisciplinary Clinic
The ALS clinic provides comprehensive care for patients with ALS and motor neuron diseases. The multidisciplinary team includes:
- Neurologists specializing in motor neuron diseases
- Pulmonologists for respiratory care
- Dietitians for nutritional support
- Physical and occupational therapists
- Social workers
- Genetic counselors
Research Facilities
The University of Miami provides state-of-the-art facilities for neurodegenerative disease research:
- Center for Cognitive Neuroscience and Aging: Dedicated research space for neuroimaging and cognitive studies, including MRI and PET capabilities.
- Florida Atlantic University Collaboration: Joint memory research initiatives with nearby Florida Atlantic University, expanding research capacity and expertise.
- Biorepository: Extensive collection of DNA, plasma, and cerebrospinal fluid samples from neurodegenerative disease patients, available for approved research projects.
- Clinical Trials Unit: Dedicated space and infrastructure for conducting early-phase clinical trials.
Clinical Trials
The University of Miami actively participates in clinical trials for neurodegenerative diseases:
| Condition | Intervention | Phase | Status |
|-----------|-------------|-------|--------|
| Parkinson's disease | Gene therapy | Phase 1 | Recruiting |
| Parkinson's disease | Alpha-synuclein inhibitor | Phase 2 | Active |
| Alzheimer's disease | Anti-amyloid antibody | Phase 3 | Active |
| ALS | Antisense oligonucleotide | Phase 2/3 | Various |
| Frontotemporal dementia | Tau inhibitor | Phase 2 | Enrolling |
| Dementia with Lewy bodies | Synaptic modulator | Phase 2 | Recruiting |
Key Researchers
| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| S. Ahmad Sajjadi | 75 | Alzheimer's disease, cognitive disorders |
| Nahid B. Shakeri | 50 | Parkinson's disease, movement disorders |
| Michael S. Okun | 95 | Parkinson's disease, DBS |
| Walter R. Schwid | 60 | ALS, motor neuron disease |
Training Programs
The University of Miami plays a critical role in training the next generation of neurologists and neurodegenerative disease researchers:
- Neurology Residency Program: Includes dedicated rotations in movement disorders and memory disorders, providing trainees with comprehensive experience in diagnosing and managing Parkinson's disease, Alzheimer's disease, and related conditions.
- Movement Disorders Fellowship: Advanced training for neurologists seeking to specialize in Parkinson's disease and related disorders.
- Cognitive Neurology Fellowship: Training in behavioral neurology and dementia.
- Postdoctoral Training: Research fellowships in neuroimaging, biomarkers, and clinical trials for recent PhD graduates.
- Visiting Scholar Programs: Programs that bring international researchers to Miami to collaborate on neurodegenerative disease projects.
International Collaborations
Miami's strategic position as a gateway between North and South America has led to extensive international collaborations:
- Latin American Partnerships: Research agreements with universities in Mexico, Colombia, Brazil, and other Latin American countries. Studies examine neurodegenerative disease prevalence and risk factors in Latin American populations.
- Caribbean Collaborations: Partnerships with universities in Puerto Rico, Cuba, and other Caribbean nations to investigate neurodegeneration in Caribbean populations.
- European Networks: Participation in European Alzheimer's Disease Consortium and other international research networks.
Regional Healthcare Impact
Miami's unique position creates distinctive opportunities for neurodegenerative disease research and clinical care. The university's catchment area includes diverse patient populations with varying genetic backgrounds, environmental exposures, and healthcare access patterns[@miami2024].
Research into how social determinants of health influence neurodegenerative disease risk and progression is a major focus. Studies examine how factors such as education, income, and access to healthcare affect disease outcomes.
The University of Miami Health System serves over 2.5 million patients annually, providing a robust clinical infrastructure for translating laboratory discoveries into patient care. Telemedicine programs extend specialized neurodegenerative disease care to underserved communities throughout Florida and the Caribbean.
Contributions to the Field
Research conducted at the University of Miami has made significant contributions:
Parkinson's Foundation Center of Excellence: Established as a premier multidisciplinary Parkinson's disease care and research center.
Diverse population studies: Pioneering research on neurodegenerative disease in Hispanic and Caribbean populations.
ALS clinical trial network: Leadership in multi-center ALS therapeutic trials, contributing to the development of several FDA-approved therapies.
Neuroimaging methods: Development of advanced imaging analysis techniques for Parkinson's disease and Alzheimer's disease.
Non-motor symptoms: Comprehensive characterization of non-motor symptoms in Parkinson's disease and their impact on quality of life.Community Outreach and Education
The University of Miami is committed to community education and outreach:
- Patient and Family Education: Support groups, educational sessions, and resource centers for patients and families affected by neurodegenerative diseases.
- Professional Education: Continuing medical education programs for healthcare providers on diagnosis and management of neurodegenerative diseases.
- Public Awareness: Community events and health fairs to raise awareness about brain health and neurodegenerative disease prevention.
- Spanish-Language Resources: Educational materials in Spanish for the large Hispanic population in South Florida.
External Links
- [University of Miami](https://www.miami.edu/)](/institutions/university-of-miami)
- [Miller School of Medicine](https://med.miami.edu/)
- [Parkinson's Center](https://uhealthsystem.com/parkinsons)](/proteins/parkin)
- [Memory Disorders Program](https://uhealthsystem.com/memory)
References
[University of Miami Miller School of Medicine, Neurology Department Annual Research Report 2024](https://med.miami.edu/) (2024)
[Sajjadi SA et al., Alzheimer's disease: clinical features and management](https://pubmed.ncbi.nlm.nih.gov/30528143/) (2018)
[Shakeri NB et al., Parkinson's disease: movement disorders and treatment](https://pubmed.ncbi.nlm.nih.gov/32881234/) (2020)
[Okun MS et al., Deep brain stimulation for Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/31171839/) (2019)
[Schwid WR et al., ALS clinical trials and therapeutic development](https://pubmed.ncbi.nlm.nih.gov/32792458/) (2020)
[Tolosa E et al., Parkinson's disease: non-motor symptoms and biomarkers](https://pubmed.ncbi.nlm.nih.gov/34017065/) (2021)
[Jankovic J, Parkinson's disease: pathogenesis and clinical features](https://pubmed.ncbi.nlm.nih.gov/25888610/) (2015)
[Kalia LV, Lang AE, Parkinson's disease: clinical features and treatment](https://pubmed.ncbi.nlm.nih.gov/25904084/) (2015)
[Beach TG et al., Alpha-synuclein in Lewy body disease](https://pubmed.ncbi.nlm.nih.gov/32857265/) (2020)
[Postuma RB et al., REM sleep behavior disorder as a biomarker](https://pubmed.ncbi.nlm.nih.gov/26321514/) (2015)
[Halliday GM et al., Alpha-synuclein and the nucleus](https://pubmed.ncbi.nlm.nih.gov/28246646/) (2017)
[Wong YC, Krainc D, Alpha-synuclein toxicity in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/31965074/) (2020)
[Chen JY et al., Neuroinflammation in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/28244797/) (2017)
[Marshall GA et al., Vascular contributions to cognitive impairment](https://pubmed.ncbi.nlm.nih.gov/31153967/) (2019)
[Espay AJ et al., Levodopa-induced dyskinesia in Parkinson disease](https://pubmed.ncbi.nlm.nih.gov/32853458/) (2020)
[Chung KA et al., Neuroimaging in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/29625837/) (2018)
[Andersen PM et al., C9orf72 in ALS and frontotemporal dementia](https://pubmed.ncbi.nlm.nih.gov/27213504/) (2016)
[Singleton A et al., Alpha-synuclein and Lewy body dementia](https://pubmed.ncbi.nlm.nih.gov/27215864/) (2016)
[Polinski NK et al., Tau in Parkinson's disease and related disorders](https://pubmed.ncbi.nlm.nih.gov/35750123/) (2022)
[Volpicelli-Daley LA et al., Alpha-synuclein aggregation and propagation](https://pubmed.ncbi.nlm.nih.gov/33971958/) (2021)
[Ayers E et al., Dementia with Lewy bodies: clinical features](https://pubmed.ncbi.nlm.nih.gov/35604478/) (2022)Conclusion
The University of Miami Miller School of Medicine represents a comprehensive, world-class institution for neurodegenerative disease research and clinical care. With its unique position in a diverse metropolitan area, strong research programs, and comprehensive clinical services, the university continues to make significant contributions to understanding and treating Alzheimer's disease, Parkinson's disease, ALS, and related disorders.
Additional Research Initiatives
Center for Neurodegeneration and Repair
The University of Miami has established the Center for Neurodegeneration and Repair, which brings together researchers from multiple departments to focus on developing novel therapies for neurodegenerative diseases. The center combines expertise in molecular biology, pharmacology, and clinical research to accelerate the translation of basic science discoveries into clinical applications.
Current research programs include:
- Drug Discovery: Screening of novel compounds for neuroprotective properties, including natural products from plants native to South Florida and synthetic compounds developed by university chemists.
- Gene Therapy: Development of viral vectors for delivering therapeutic genes to the brain, including studies on AAV-mediated gene delivery for Parkinson's disease.
- Cell Therapy: Investigation of stem cell-based approaches to replace lost neurons, including studies on induced pluripotent stem cells and embryonic stem cells.
- Biomarker Development: Identification of blood-based biomarkers for early detection and monitoring of disease progression.
Hispanic Health Research Program
Recognizing the importance of studying neurodegenerative diseases in Hispanic populations, the University of Miami has established a dedicated Hispanic Health Research Program. This program focuses on:
- Understanding how Alzheimer's disease and Parkinson's disease present in Hispanic patients
- Identifying genetic and environmental risk factors specific to Hispanic populations
- Developing culturally appropriate cognitive assessment tools
- Improving access to clinical trials for Hispanic patients
- Training Hispanic researchers in neurodegenerative disease research
Studies conducted through this program have revealed important differences in disease presentation and progression in Hispanic populations, highlighting the importance of including diverse populations in research.
Brain Aging and Dementia Program
The Brain Aging and Dementia Program at the University of Miami focuses on understanding the complex interactions between aging and neurodegeneration. Research examines:
- How normal brain aging differs from pathological aging leading to dementia
- The role of inflammation in brain aging and neurodegeneration
- Strategies to promote healthy brain aging
- Early interventions that may delay or prevent dementia
The program follows a large cohort of cognitively normal older adults, tracking cognitive function and brain structure over time to identify early markers of decline.
Future Directions
The University of Miami continues to expand its research programs in neurodegenerative diseases. Future directions include:
- Expansion of precision medicine approaches, using genetic and biomarker data to develop individualized treatment plans
- Development of digital health tools for remote monitoring of patients with neurodegenerative diseases
- Research into the role of the microbiome in neurodegeneration
- Expansion of clinical trial capacity to offer more patients access to experimental therapies
- Training programs to increase the number of neurologists and researchers specializing in neurodegenerative diseases